NCT07079618View on ClinicalTrials.gov

A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

August 31, 2025

Conditions
Anterior Myocardial Infarction
Interventions
DRUG

SGC001

In this study, 6 dose groups are planned. 8 subjects are enrolled in each group. A total of 48 subjects will be enrolled. The administration method for each group is as follows: The drug SGC001 should be administered once via intravenous injection within 6 hours and the administration time 10 minutes.

DRUG

Placebo

In this study, 6 dose groups are planned. 8 subjects are enrolled in each group. A total of 48 subjects will be enrolled. The administration method for each group is as follows: The drug placebo should be administered once via intravenous injection within 6 hours and the administration time 10 minutes.

Trial Locations (1)

100013

Beijing Anzhen Hospital Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Sungen Biomedical Technology Co., Ltd

INDUSTRY

NCT07079618 - A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects | Biotech Hunter | Biotech Hunter